Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04268290
Other study ID # NFEC-2019-156
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date February 15, 2020
Est. completion date February 15, 2022

Study information

Verified date November 2019
Source Nanfang Hospital of Southern Medical University
Contact Wang Yanan, M.D
Phone +86-131-8909-6629
Email wyn8116@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Conventional laparoscopic surgery (CLS) for colorectal cancer has been demonstrated to be safe and feasible and present minimally invasive benefits including faster recovery, reduced postoperative pain and shorter hospital stay, also acquiring comparable oncologic outcomes with open surgery. To achieve further minimally invasive outcomes, SILS plus one port surgery was attempted by some surgeons. Preliminary results showed that SILS+1 could achieve better minimally invasive benefits than CLS while preserving oncologic feasibility.

Till now, ERAS has been practiced in colorectal cancer surgery for approximately 20 years. Studies have proven that ERAS is safe and significantly improved the recovery course of patients during perioperative period, meanwhile, the expense could be greatly reduced.

Based on ERAS studies protocols and SILS+1 trials, investigators tried to combine SILS+1 with ERAS, hopefully to provide patients with more safe, economic, feasible and rapid surgery and perioperative strategies.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date February 15, 2022
Est. primary completion date February 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Primary tumor diagnosed as adenocarcinoma confirmed pathologically by endoscopic biopsy

- cT1-4a, N0-3, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual Seventh Edition

- Located in the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, the upper segment of the rectum.

- Diameter ? 5cm

- No severe organ dysfunction

- Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale

- ASA (American Society of Anesthesiology) score class I or II

- Written informed consent

Exclusion Criteria:

- Unsuitable for patients undergoing single incision plus one port laparoscopic surgery

- Patients with Complications caused by colorectal cancer ( bleeding , perforation, obstruction or incomplete obstruction )

- Previous abdominal surgery

- Malignant diseases within the past 5years

- Requirements of simultaneous surgery for another diseases

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Single incision plus one port laparoscopic surgery
SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Nanfang Hospital of Southern Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary Rehabilitative rate The percentage of patients who met discharge criteria in the fourth day after surgery 4 days
Primary Postoperative hospital stays Days from surgery to discharge 1 month
Secondary Medical cost The patient's expenses from surgery to discharge are recorded in RMB "yuan" 1 month
Secondary Postoperative pain score Postoperative pain is recorded using the visual analog scale (VAS) pain score tool on postoperative day . On a scale of 1 to 10, the higher the score, the greater the pain. Once a day from 6 hours to the fourth day after surgery
Secondary Postoperative recovery index The first Time to early mobilization(hour), flatus(hour), liquid diet(hour), soft diet(hour), removal of the Nasogastric tubes(hour) , removal of the peritoneal drainage(hour) are used to assess the postoperative recovery 1 month
Secondary Postoperative inflammatory immune response It includes the number of white blood cells and lymphocytes,CRP, IL-6 3 days
Secondary compliance with ERAS measures It is defined as if the patients complete every ERAS measure or not. We can defined it "yes " or "not". perioperative
Secondary 6 min postoperative walking test(6MWT) Study site, subject preparation, trial procedures, and medical monitoring refer to the 6MWT guidelines issued by the American thoracic society in 2002. Once a day from the frist to the fourth day after surgery
Secondary hospital readmissions It can be defined as the number of patients readmitted within 30 days because of postoperative complications. 30days
Secondary Morbidity and mortality rates Morbidity and mortality rates are defined as postoperative complications graded according to Clavien-Dindo within 30 days. 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A